BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38258815)

  • 1. The Impact of Completing X-Waiver Training and Clinical Addiction Exposure on Internal Medicine Residents Treating Patients With Opioid Use Disorder.
    Callister C; Porter S; Vatterott P; Keniston A; McBeth L; Mann S; Calcaterra SL; Limes J
    Subst Use Addctn J; 2024 Jul; 45(3):356-366. PubMed ID: 38258815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Training in Safe Opioid Prescribing and Treatment of Opioid Use Disorder in Internal Medicine Residencies: a National Survey of Program Directors.
    Windish DM; Catalanotti JS; Zaas A; Kisielewski M; Moriarty JP
    J Gen Intern Med; 2022 Aug; 37(11):2650-2660. PubMed ID: 34729698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid stewardship training during the transition to residency to prepare medical students to recognize and treat opioid use disorder.
    Estave PM; Jacobs ML; Rukstalis M; Goforth J; Stone SN; Choi JA; Barrett J; Douglas HE; Oliver JB; Keating MK; Freischlag JA; O'Brien MC; McEwen S; Strowd RE
    Subst Abus; 2021; 42(4):1040-1048. PubMed ID: 34236292
    [No Abstract]   [Full Text] [Related]  

  • 5. The Impact on Future Prescribing Patterns of Opioid Use Disorder (OUD) Education and Waiver Provision During Residency.
    Boggiano V; Gilmore Wilson C; Fagan EB; Kirk J; Bossenbroek-Fedoriw K; Tak CR
    J Am Board Fam Med; 2020; 33(6):998-1003. PubMed ID: 33219079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eight-hour medication-assisted treatment waiver training for opioid use disorder: integration into medical school curriculum.
    Lien IC; Seaton R; Szpytman A; Chou J; Webber V; Waineo E; Levine D
    Med Educ Online; 2021 Dec; 26(1):1847755. PubMed ID: 33222656
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of Resident Physicians' Knowledge of and Attitudes Towards Prescribing Buprenorphine for Patients With Opioid Use Disorder.
    Shuey B; Lee D; Ugalde I; Borgan S; Bresnan C; Qureshi M; Mhaskar R; Oxner A
    J Addict Med; 2021 May-Jun 01; 15(3):219-225. PubMed ID: 33079729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey.
    Foti K; Heyward J; Tajanlangit M; Meek K; Jones C; Kolodny A; Alexander GC
    Drug Alcohol Depend; 2021 Aug; 225():108811. PubMed ID: 34175786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.
    Franz B; Dhanani LY; Hall OT; Brook DL; Simon JE; Miller WC
    Harm Reduct J; 2023 Dec; 20(1):180. PubMed ID: 38129903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice.
    Pytell JD; Buresh ME; Graddy R
    Addict Sci Clin Pract; 2019 Dec; 14(1):46. PubMed ID: 31856915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.
    Lanham HJ; Papac J; Olmos DI; Heydemann EL; Simonetti N; Schmidt S; Potter JS
    JAMA Netw Open; 2022 May; 5(5):e2212419. PubMed ID: 35552721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX.
    Potter JS; Finley EP; King VL; Lanham HJ; Schmidt S; Schneegans S; Rosen KD
    J Subst Abuse Treat; 2022 Jun; 137():108688. PubMed ID: 35058105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Training in Buprenorphine and Office-Based Opioid Treatment: A Survey of Psychiatry Residency Training Programs.
    Suzuki J; Ellison TV; Connery HS; Surber C; Renner JA
    Acad Psychiatry; 2016 Jun; 40(3):498-502. PubMed ID: 26017618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage.
    Calcaterra SL; Lockhart S; Natvig C; Mikulich S
    J Hosp Med; 2023 Oct; 18(10):896-907. PubMed ID: 37608527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing the opioid crisis: An assessment of clinicians' training experience, practices, and attitudes within a large healthcare organization.
    Kirane H; Drits E; Ahn S; Kapoor S; Morgenstern J; Conigliaro J; Enden J
    J Opioid Manag; 2019; 15(3):193-204. PubMed ID: 31343721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating DATA 2000 waiver training into undergraduate medical education: The time is now.
    Riser E; Holterman LA; Maruti S; Brooklyn JR; DeVoe SG; Tompkins BJ; Drouin J; Sobel HG
    Subst Abus; 2021; 42(2):236-243. PubMed ID: 33821773
    [No Abstract]   [Full Text] [Related]  

  • 18. Barriers and Facilitators to Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine.
    Hawk KF; D'Onofrio G; Chawarski MC; O'Connor PG; Cowan E; Lyons MS; Richardson L; Rothman RE; Whiteside LK; Owens PH; Martel SH; Coupet E; Pantalon M; Curry L; Fiellin DA; Edelman EJ
    JAMA Netw Open; 2020 May; 3(5):e204561. PubMed ID: 32391893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine Waiver Attitudes Among Primary Care Providers.
    Lai B; Croghan I; Ebbert JO
    J Prim Care Community Health; 2022; 13():21501319221112272. PubMed ID: 35822763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.